Sign in
Taking people in South KoreaNo phase

Reviewing past treatment and survival in people with high-grade osteosarcoma

Looks back at records of people treated for high-grade osteosarcoma in Korea.

Key facts

Who runs it
MedPacto, Inc.
Where
Goyang-si and Seoul, South KoreaSee the 4 sites
Trial code
Registry title
Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study
Status
Recruiting
People taking part
400 people, planned
Started
13 Jul 2026
Expected to end
31 Dec 2027
Type of study
Observational
Record updated
16 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

This record-review study looks at people aged 12 or older with high-grade osteosarcoma (a bone cancer). Their first treatment had to be completed or ended at a study hospital on or before 2021-06-30.

Age
12 years or older
Sex
All sexes can join
Disease stage
High-grade osteosarcoma confirmed by pathology (tissue examination)
Earlier treatment
First-line treatment for high-grade osteosarcoma completed or ended at the study hospital on or before 2021-06-30

Main reasons for not taking part

  • Primary tumor that began in soft tissue rather than bone
  • Another cancer in the past, unless clinically insignificant and fully treated before the osteosarcoma
  • Key data for the survival analysis cannot be verified
  • Moved to another hospital with no follow-up information available
  • Data errors or inconsistencies judged by the investigator

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Pathologically diagnosed high-grade osteosarcoma; age ≥12 years
  • First-line treatment for high-grade osteosarcoma completed or ended at the study institution on or before 2021-06-30
  • Core data required for survival endpoint assessment (EFS, PFS, OS) are available, with at least one of the following satisfied: (a) at least 12 months of follow-up from the date of diagnosis; or (b) an event (relapse, metastasis, disease progression, or death from any cause) confirmed within 12 months of diagnosis

Who cannot take part

  • History of a malignancy other than primary osteosarcoma, unless clinically insignificant and fully treated prior to osteosarcoma diagnosis with no investigator-judged impact on osteosarcoma treatment course or survival analysis
  • Primary tumor of soft-tissue origin rather than bone, confirmed pathologically
  • Core data required for survival analysis cannot be verified
  • Transferred to another institution with no available follow-up information, where neither event occurrence, last follow-up date, nor survival status can be determined from pre-transfer records
  • Investigator-judged data errors or inconsistencies

Where in South Korea

  • National Cancer CenterGoyang-si, South KoreaContact: Prof. June-Hyuk KimTaking people
  • Asan Medical CenterSeoul, South KoreaContact: Prof. Kyung-Nam KohNot yet recruiting
  • Korea Cancer Center HospitalSeoul, South KoreaContact: Prof. Wan-Hyeong ChoTaking people
  • Seoul National University HospitalSeoul, South KoreaContact: Prof. Hyoung-Jin KangNot yet recruiting

About the trial

What the trial wants to find out

This is a multicenter, medical-record-based, retrospective observational study of approximately 400 patients with high-grade osteosarcoma treated at four sites in the Republic of Korea. The study describes treatment patterns and survival outcomes (event-free survival [EFS], progression-free survival [PFS], and overall survival [OS]) in patients who completed or discontinued first-line treatment for high-grade osteosarcoma, irrespective of complete remission status. The primary objective is to retrospectively estimate the 12-month EFS rate, calculated from the date of diagnosis, in the full cohort of high-grade osteosarcoma patients. Key secondary objectives evaluate EFS and OS from the date of confirmed complete remission/no evidence of disease (CR/NED) in the subset of clinically high-risk patients who achieve CR/NED, in order to establish a historical reference data supporting the design and interpretation of a future prospective clinical trial of vactosertib as maintenance therapy.

The group in the trial

  • High-grade Osteosarcoma Cohort

    Retrospectively identified patients with high-grade osteosarcoma who meet the study eligibility criteria.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter Medical-Record-Based Retrospective Study of Treatment Patterns and Survival Outcomes in Patients With High-Grade Osteosarcoma
Plain-language title
Reviewing past treatment and survival in people with high-grade osteosarcomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
16 October 2026